First Time Loading...

Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 24.58 USD -0.45% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

BCYC Price Targets Summary
Bicycle Therapeutics PLC

Wall Street analysts forecast BCYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCYC is 44.06 USD with a low forecast of 30.3 USD and a high forecast of 63 USD.

BCYC Lowest Forecast
Wall Street Target
30.3 USD
23% Upside
BCYC Average Forecast
Wall Street Target
44.06 USD
79% Upside
BCYC Highest Forecast
Wall Street Target
63 USD
156% Upside
Lowest
Price Target
30.3 USD
23% Upside
Average
Price Target
44.06 USD
79% Upside
Highest
Price Target
63 USD
156% Upside
Bicycle Therapeutics PLC Competitors:
Price Targets
CRIS
Curis Inc
36% Upside
C
049960
Cell Biotech Co Ltd
364% Upside
ARGX
argenx SE
28% Upside
BMRN
Biomarin Pharmaceutical Inc
36% Upside
CRIS
Curis Inc
36% Upside
C
049960
Cell Biotech Co Ltd
364% Upside
ARGX
argenx SE
28% Upside
BMRN
Biomarin Pharmaceutical Inc
36% Upside
ICCC
ImmuCell Corp
178% Upside
KNTE
Kinnate Biopharma Inc
9% Downside
2256
Abbisko Cayman Ltd
150% Upside
EXAI
Exscientia PLC
89% Upside

Revenue
Forecast

Revenue Estimate
Bicycle Therapeutics PLC

For the last 6 years the compound annual growth rate for Bicycle Therapeutics PLC's revenue is 54%. The projected CAGR for the next 3 years is 17%.

54%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Bicycle Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Bicycle Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-36%
Average Miss
What are analyst estimates?

See Also

Summary
BCYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
BCYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BCYC stock valuation using valuation multiples.
Wall Street Estimates
BCYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BCYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BCYC's stock price target?
Price Target
44.06 USD

According to Wall Street analysts, the average 1-year price target for BCYC is 44.06 USD with a low forecast of 30.3 USD and a high forecast of 63 USD.

What is Bicycle Therapeutics PLC's Revenue forecast?
Projected CAGR
17%

For the last 6 years the compound annual growth rate for Bicycle Therapeutics PLC's revenue is 54%. The projected CAGR for the next 3 years is 17%.

ALPHA SPREAD
Join more than 134,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.